These patients tended to have higher copy number alterations and/or tumor mutation burden in their metastatic disease after PIKTOR treatment, loss of DNA damage signatures, and increased expression of PD-1/PD-L1 pathway genes, with significant decreases in DNA damage response, stress and proliferation proteins. This evidence concerns the gene CD274 and metastatic neoplasm.